Holoye P Y, Samuels M L
Chest. 1975 Jun;67(6):675-9. doi: 10.1378/chest.67.6.675.
Thirty-nine patients with small cell lung cancer were treated with large dose intravenous cyclophosphamide combined with vincristine. Sequential split-course radiotherapy was added when the gross disease was limited to one hemithorax and draining scalene nodes. Fifteen of 16 patients in the limited disease category showed objective response, eight of which were complete. Fourteen of 23 patients in the extensive disease category yielded an objective response, six of which were complete. The median survival for complete responders was 48 weeks, 38 weeks for partial responders and 14 weeks for non-responders. The difference between responders and non-responders was statistically significant. The major toxicity was myelosuppression with a median leukocyte nadir of 500/mm-3 noted on treatment day no. 15. Prompt recovery was the rule. Toxicity appeared to be cumulative for patients receiving radiotherapy. These results are superior to those evolving from treatment with cyclophosphamide as a solitary agent.
三十九例小细胞肺癌患者接受了大剂量静脉注射环磷酰胺联合长春新碱治疗。当大体病变局限于一侧胸腔及引流的斜角肌淋巴结时，加用序贯分段放疗。16例局限性疾病患者中有15例出现客观缓解，其中8例完全缓解。23例广泛性疾病患者中有14例出现客观缓解，其中6例完全缓解。完全缓解者的中位生存期为48周，部分缓解者为38周，无缓解者为14周。缓解者与无缓解者之间的差异具有统计学意义。主要毒性为骨髓抑制，在第15个治疗日观察到白细胞计数最低点的中位数为500/mm³。迅速恢复是常见情况。接受放疗的患者毒性似乎具有累积性。这些结果优于单独使用环磷酰胺治疗的结果。
